Ordering
Available Variants5 mg
CHA.98095-5mg
Price
€84.00
Available – Dispatch in 14 days
25 mg
CHA.98095-25mg
Price
€408.00
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.98095-5mg | €84.00 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.98095-25mg | €408.00 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C24H21Cl2N5O2 |
|---|---|
| CAS Number | 305820-75-1 |
| Molecular Weight | 482.36 |
| NACRES | NA.77 |
| PubChem Substance ID | 329823705 |
| UNSPSC Code | 12352200 |
| MDL number | MFCD16875428 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
PD173952, also known by its CAS number 305820-75-1, is a potent and selective inhibitor of fibroblast growth factor receptor 1, exhibiting high affinity for the ATP-binding site of the enzyme. This compound has been investigated for its potential therapeutic applications, particularly in the treatment of various types of cancer, where aberrant fibroblast growth factor receptor activity is often implicated. PD173952 has demonstrated significant inhibitory effects on the proliferation of cancer cells in vitro, and its ability to induce apoptosis in these cells suggests a potential mechanism of action. Further studies are necessary to fully elucidate the pharmacological properties and potential clinical utility of PD173952, but its selective inhibition of fibroblast growth factor receptor 1 makes it an interesting candidate for further development as a targeted cancer therapy. Its biochemical properties make it a valuable tool for research.
